ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
54 announcements
Revenue grew a healthy 23.5%, but adjusted EBITDA lagged and H1 margin fell about 80bps to 23%. Management deflected on pricing, FX and margin detail, relying on 'healthy range' language and long-term guidance.
Nephrocare filed Crisil's monitoring agency report on IPO proceeds for the quarter ended 30 September 2026. The report shows no deviation from the stated objects.
H1FY27 revenue ₹585.2 Cr (+23.6% YoY), Adj EBITDA ₹134.4 Cr (+15.3%), Adj PAT ₹76.1 Cr (+34.7%). Expansion via acquisitions in Philippines, Kazakhstan and Saudi Arabia.
Nephrocare Health Services released its Q2 and H1 FY27 results press release. Revenue and adjusted profit grew year-on-year, alongside network expansion into Kazakhstan.
Nephrocare Health Services Ltd reported revenue from operations of ₹303.4 Cr (+23.5% YoY) and net profit of ₹33.5 Cr for Q2 FY27.
Nephrocare's Uzbek subsidiary won a court ruling invalidating a ₹14.79 crore tax demand. The tax department must reconsider the audit, and the decision remains appealable.
Nephrocare's Philippines subsidiary agreed to acquire dialysis center assets from JCM Summit Health under an Asset Transfer Agreement. Consideration is undisclosed but the deal exceeds materiality thresholds.
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Nephrocare Health Services intimated that its Board is scheduled for 3 Nov 2026 to consider Q2/H1 FY27 results. The trading window remains closed from 1 Oct to 5 Nov 2026.
Polar Capital Funds PLC acquired 2,549,478 shares (2.535%) in Nephrocare Health Services Ltd through an off-market placing. This acquisition increases their total stake to 8.311%.
India Ratings upgraded Nephrocare Health Services' long-term bank loan facilities to IND AA-/Stable. The agency also affirmed the company's short-term credit ratings.
Nephrocare Health Services Ltd announced the rationalisation and consolidation of its step-down subsidiaries in the Philippines. This internal reorganization streamlines the group's existing structure.
Nephrocare's Philippines subsidiary acquired a dialysis center from Renal One Dialysis Corp for ≈₹10.25 Cr. The asset transfer expands the company's dialysis network.
Nephrocare's Philippines subsidiary is acquiring a dialysis center from Renal One Dialysis Corp. for a consideration of ₹10.25 crore.
Nephrocare Health Services granted 4,01,362 employee stock options at an exercise price of ₹230 per share. These options are issued under the NephroPlus Employee Stock Option Scheme 2026.
Nephroplus Health Services Kazakhstan LLP will acquire a 100% stake in 'Dialysis Center Almaty' LLP for approximately ₹11.64 Crore to expand its international dialysis network.
Nephrocare Health Services' subsidiary in Uzbekistan received a tax assessment order. The total financial exposure, including tax and penalties, is approximately ₹14.79 Crore.
Nephrocare Health Services' Philippines subsidiary acquired a dialysis center's assets for PhP 75 million. The transaction strengthens the company's international footprint in the healthcare sector.
Nephrocare Health Services' subsidiary entered an agreement to acquire a dialysis center in Philippines from Assumption Dialysis Center. The transaction is valued at PhP 75,000,000.
Nephrocare Health Services' subsidiary acquired dialysis center assets from Assumption Dialysis Center in the Philippines. The transaction is valued at PhP 75 million (approximately ₹13.50 Crore).
Nephrocare Health Services' overseas step-down subsidiary signed an Asset Transfer Agreement to acquire assets of Juan Nephro Dialysis Center for PhP 71.8 million.
Nephrocare Health Services entered an Asset Transfer Agreement to acquire a dialysis center in Philippines. The acquisition is valued at PHP 71,800,000.
Nephrocare Health Services Limited held its 17th Annual General Meeting on August 12, 2026. The meeting transacted various business items, including adoption of financial statements and director re-appointment.
Nephrocare delivered robust 23.7% revenue growth driven by international expansion and volume gains. While margins improved via operating leverage, high working capital cycles and binary outcomes in tender markets like Saudi Arabia remain key risks.
Nephrocare Health Services' subsidiary NPKSC will acquire a 51% stake in NHSSAC for ₹5.69 Crore. This internal restructuring aims to optimize the Group's Saudi Arabia operations.
Nephrocare Health Services reported Q1FY27 revenue of ₹281.8 crore and adjusted PAT of ₹36.8 crore. The dialysis network grew revenue 23.7% YoY.
Nephrocare Health Services (NephroPlus) reported Q1FY27 revenue of ₹281.8 Cr, up 23.7% YoY. Strategy focuses on international scaling and high-margin organized dialysis network leadership.
Nephrocare Health Services Ltd reported revenue from operations of ₹281.8 Cr (+23.7% YoY) and net profit of ₹32 Cr (+35.0% YoY) for Q1 FY27.
Nephrocare Health Services disclosed trading plans from designated persons Rohit Singh and Sukaran Singh Saluja. The plans outline potential share sales scheduled for December 2026.
Nephrocare Health Services scheduled a board meeting for August 11, 2026. The board will consider the June 30, 2026, quarterly financial results.